Your session is about to expire
← Back to Search
eltrombopag olamine for Acute Myeloid Leukemia
Study Summary
This trial looks at how well a drug works in improving the recovery of platelet counts in older patients with Acute Myeloid Leukemia undergoing induction chemotherapy.
- Acute Myeloid Leukemia
- Acute Basophilic Leukemia
- Megakaryoblastic Leukemia
- Monoblastic Leukemia
- Monocytic Leukemia
- Adult Acute Myeloid Leukemia
- Acute Myelomonocytic Leukemia
- Erythroleukemia
- Acute Myeloblastic Leukemia
- Leukemia
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are currently involved in another study testing a new treatment.You have received previous treatment with certain medications called recombinant thrombopoietin or TPO-receptor agonists.You have had a bad allergic reaction to drugs similar to eltrombopag or its ingredients.You have received radiation therapy, strong chemotherapy, or a combination of both to treat another cancer or medical condition within the past year. However, the use of hydroxyurea or leukapheresis for certain situations is allowed. If you were treated with all-trans retinoic acid (ATRA) for a suspected diagnosis of acute promyelocytic leukemia (APL), but it was later confirmed that you do not have APL, you may still be eligible for the study.In the past year, you have had a blood clot in an artery or vein, except for clots related to medical lines. This includes clots in the lungs, legs, heart, brain, liver, kidneys, spleen, or other organs.
- Group 1: Supportive care (eltrombopag olamine)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
When was eltrombopag olamine FDA approved?
"While there is some data suggesting eltrombopag olamine is safe, efficacy has not been proven. Therefore, it received a score of 2."
How many people are receiving treatment as part of this experiment?
"Unfortunately, this trial is no longer recruiting patients. It was initially posted on 8/14/2014 but the most recent edit was on 11/29/2021. However, there are 1672 other trials for leukemia, erythroblastic, acute and 25 eltrombopag olamine trials that are still enrolling patients if you're seeking an active clinical study."
Are patients able to enroll in this clinical trial at this time?
"Data on clinicaltrials.gov reveals that this study is not open for recruitment at this time. The trial was initially posted on 8/14/2014 and last updated on 11/29/2021. Although this particular study isn't looking for patients right now, there are 1697 other studies which are."
Share this study with friends
Copy Link
Messenger